国际呼吸杂志
國際呼吸雜誌
국제호흡잡지
INTERNATIONAL JOURNAL OF RESPIRATION
2015年
4期
316-320
,共5页
非小细胞肺癌%程序性死亡受体-1%程序性死亡配体-1
非小細胞肺癌%程序性死亡受體-1%程序性死亡配體-1
비소세포폐암%정서성사망수체-1%정서성사망배체-1
Non-small cell lung cancer%Programmed death receptor-1%Programmed death ligand-1
程序性死亡受体-1(PD-1)/程序性死亡配体-1(PD-L1)信号途径参与肿瘤的免疫逃逸。PD-L1蛋白在非小细胞肺癌组织中存在不同程度的表达,其表达程度与肿瘤细胞的分化程度、临床分期、淋巴转移及预后等相关联。PD-L1可能通过保持非小细胞肺癌肿瘤浸润性树突状细胞的不成熟状态,增强调节性 T 细胞功能,与浸润性淋巴细胞表面高表达的 PD-1相互作用诱导 CD8+ T 细胞凋亡等机制介导肺癌的免疫豁免。目前针对 PD-1/PD-L1途径的临床免疫治疗试验已经在非小细胞肺癌中取得一定的疗效,成为非小细胞肺癌免疫治疗的新靶向。
程序性死亡受體-1(PD-1)/程序性死亡配體-1(PD-L1)信號途徑參與腫瘤的免疫逃逸。PD-L1蛋白在非小細胞肺癌組織中存在不同程度的錶達,其錶達程度與腫瘤細胞的分化程度、臨床分期、淋巴轉移及預後等相關聯。PD-L1可能通過保持非小細胞肺癌腫瘤浸潤性樹突狀細胞的不成熟狀態,增彊調節性 T 細胞功能,與浸潤性淋巴細胞錶麵高錶達的 PD-1相互作用誘導 CD8+ T 細胞凋亡等機製介導肺癌的免疫豁免。目前針對 PD-1/PD-L1途徑的臨床免疫治療試驗已經在非小細胞肺癌中取得一定的療效,成為非小細胞肺癌免疫治療的新靶嚮。
정서성사망수체-1(PD-1)/정서성사망배체-1(PD-L1)신호도경삼여종류적면역도일。PD-L1단백재비소세포폐암조직중존재불동정도적표체,기표체정도여종류세포적분화정도、림상분기、림파전이급예후등상관련。PD-L1가능통과보지비소세포폐암종류침윤성수돌상세포적불성숙상태,증강조절성 T 세포공능,여침윤성림파세포표면고표체적 PD-1상호작용유도 CD8+ T 세포조망등궤제개도폐암적면역활면。목전침대 PD-1/PD-L1도경적림상면역치료시험이경재비소세포폐암중취득일정적료효,성위비소세포폐암면역치료적신파향。
The programmed death receptor-1(PD-1)/programmed death ligand-1(PD-L1)signaling pathway involves in tumor immune escape.The level of PD-L1 is different in non-small cell lung cancer, the expression of PD-L1 may be associated with the degree of tumor cell differentiation,clinical stage, lymph node metastasis,and prognosis.Expression of PD-L1 in non-small cell lung cancer mediate immune function exemption by remaining immature state of tumor-infiltrating dendritic cells,enhancing the function of regulatory T cells,and inducing CD8 + T cell apoptosis through interaction with PD-1 highly expressed on infiltrating lymphocyte surface and other mechanisms.Currently immunotherapy clinical trials for PD-1/PD-L1 pathway has already achieved certain effect in non-small cell lung cancer,becoming the new target for immunotherapy.